Powered by Xconomy, November 2019’s What’s Next in Neuroscience Therapies event brought together scientists, entrepreneurs and biotech executives at the Hyatt Regency San Francisco to discuss their work developing next-generation neuroscience therapies and technologies in areas such as spinal-cord injuries, precision mental health, dementia and Alzheimer’s disease.

Two former executives of biotech company MiMedx Group Inc. were criminally charged with fraudulently inflating the company’s revenue.

For Halloween, BioSpace collected six tales of thrills and chills from the pharma and biotech industries that will surely have you covering your eyes in terror.

After multiple failures to develop therapeutics for Alzheimer’s disease, Biogen’s Michael D. Ehlers resigned from his role as head of research and development.

Trucode Gene Repair Inc. emerged from stealth mode with $34 million in financing to bolster the biotech startup’s triplex gene-editing technology.

Bristol-Myers Squibb has partnered with biotech accelerator BioMotiv. Bristol-Myers will become a limited partner of BioMotiv, investing in projects of mutual interest, with an option to buy the new companies that are funded and formed once there is a preclinical candidate.

Pfizer Inc. is investing $500 million to expand a manufacturing facility in Sanford, North Carolina, that plays a central role in the company’s efforts to become a major player in gene therapy.

Leading scientists, public policy experts and biotech industry leaders joined forces to launch “Working to Fight AMR,” a coalition working to raise public awareness of the growing threat posed by antimicrobial resistance.

German drugmaker Bayer is paying up to $600 million for full control of cell therapy developer BlueRock Therapeutics.